

E4

30. (Twice Amended) A compound as claimed in claim 1, wherein at least one antigen binding [region] region(s) and at least one prodrug-activating enzyme form an sFv-β-lactamase fusion protein.

REMARKS

The amendments to claims 3 and 30 have been made to more particularly claim what Applicants regard as their invention. The amendments to claims 18 and 20-22 have been made to remove multiple dependencies.

Applicants' remarks and arguments filed in the Amendment After Final dated January 5, 2001, are herein incorporated by reference in their entirety. Accompanying this Preliminary Amendment is an Information Disclosure Statement providing the references referred to in Applicants' January 5, 2001, Amendment After Final.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 7, 2001

By: Lara C. Kelley
Lara C. Kelley
Reg. No. 41,551

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202 408-4000